Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daraxonrasib + SNV1521 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daraxonrasib | Rasonque | RMC 6236|RMC6236|RMC-6236 | RAS Inhibitor (Pan) 17 | Rasonque (daraxonrasib) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). Rasonque (daraxonrasib) is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
| SNV1521 | SNV-1521|SNV 1521 | PARP-1 Inhibitor 13 | SNV1521 selectively inhibits PARP1, potentially resulting in decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 5725). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07756281 | Phase I | Daraxonrasib + SNV1521 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | Recruiting | USA | 0 |